EXTEND DISEASE-FREE SURVIVAL
WITH THE FIRST AND ONLY ADJUVANT TARGETED TREATMENT FOR ALK+ NSCLC1,2
ALECENSA significantly reduced the risk of disease recurrence or death by 76% compared
with platinum-based chemotherapy2
ALINA disease-free survival: ITT (Stage IB–IIIA)2,*

Median survival follow-up was 27.8 months for ALECENSA and 28.4 months for chemotherapy2
94% of patients are DISEASE FREE AT Year 2 with ALECENSA2
ALINA disease-free survival: ITT (Stage IB–IIIA)2,*
.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/alecensa-2/en/images/ALINAmobileversiongraphs_DFSITT(StageIB–IIIA).png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/alecensa-2/en/images/ALINAmobileversiongraphs_DFSITT(StageIB–IIIA).png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
Median survival follow-up was 27.8 months for ALECENSA and 28.4 months for chemotherapy2
94% of patients are DISEASE FREE AT Year 2 with ALECENSA2
ITT (Stage IB–IIIA)2,* |
Stage II-IIIA ALK+ NSCLC2,* |
|||
---|---|---|---|---|
ALECENSA |
Chemotherapy |
ALECENSA |
Chemotherapy |
|
Patient number, n |
130 | 127 | 116 | 115 |
Median disease-free survival (95% CI), months |
NE (95% CI: NE, NE) |
41.3 (95% CI: 28.5, NE) |
NE (95% CI: NE, NE) |
44.4 (95% CI: 28.7, NE) |
Disease-free survival HR (95% CI) |
HR=0.24 (95% CI: 0.13, 0.43), p<0.001 |
HR=0.24 (95% CI: 0.13, 0.45), p<0.001 |
||
No filter results
OS data were not mature at the time of the primary DFS analysis with 2.3% of deaths reported overall2
Discover
ALECENSA IN
ALK+ RESECTED NSCLC
*Stage IB (tumours ≥4 cm), II or IIIA NSCLC classified according to the 7th edition of the UICC/AJCC.2
AJCC: American Joint Committee on Cancer; ALK: anaplastic lymphoma kinase; CI: confidence interval; CNS: central nervous system; DFS: disease-free survival; HR: hazard ratio; ITT: intention-to-treat; NE: not estimable; NSCLC: non-small cell lung cancer; OS: overall survival; SmPC: Summary of Product Characteristics; UICC: Union for International Cancer Control.
1. Roche. ALECENSA (alectinib) Summary of Product Characteristics. 2024. Available here (accessed July 2024); 2. Wu Y-L, et al. N Engl J Med 2024;390(14):1265–1276.
- © 2024 F. Hoffmann-La Roche Ltd.
- M-XX-00017982; Date of preparation: July 2024
- Legal Statement
- Privacy Policy
- Cookies Preferences
ALECENSA provided CONSISTENT DFS BENEFIT across Stage IB through to Stage IIIA2,*
ALINA: Disease-free survival (Stage IB)2,†

- In a prespecified exploratory subgroup analysis of patients with Stage IB disease, the Year 2 DFS rate was 92.3% for ALECENSA (95% CI: 77.8, 100.00) and 71.6% for chemotherapy (95% CI: 44.2, 98.9)2
92% of patients (stage IB) are DISEASE FREE AT Year 2 with ALECENSA2
ALINA: Disease-free survival (Stage II)2,†

- In a prespecified exploratory subgroup analysis of patients with Stage II disease, the Year 2 DFS rate was 95.6% for ALECENSA (95% CI: 89.5, 100.0) and 66.3% for chemotherapy (95% CI: 51.7, 81.0)2
96% of patients (stage II) are DISEASE FREE AT Year 2 with ALECENSA2
ALINA: Disease-free survival (Stage IIIA)2,†

- In a prespecified exploratory subgroup analysis of patients with Stage IIIA disease, the Year 2 DFS rate was 92.7% for ALECENSA (95% CI: 86.4, 98.9) and 60.7% for chemotherapy (95% CI: 47.9, 73.5)2
93% of patients (stage IIIA) are DISEASE FREE AT Year 2 with ALECENSA2
ALINA: Disease-free survival (Stage IB)2,†

- In a prespecified exploratory subgroup analysis of patients with Stage IB disease, the Year 2 DFS rate was 92.3% for ALECENSA (95% CI: 77.8, 100.00) and 71.6% for chemotherapy (95% CI: 44.2, 98.9)2
92% of patients (stage IB) are DISEASE FREE AT Year 2 with ALECENSA2
ALINA: Disease-free survival (Stage II)2,†

- In a prespecified exploratory subgroup analysis of patients with Stage II disease, the Year 2 DFS rate was 95.6% for ALECENSA (95% CI: 89.5, 100.0) and 66.3% for chemotherapy (95% CI: 51.7, 81.0)2
96% of patients (stage II) are DISEASE FREE AT Year 2 with ALECENSA2
ALINA: Disease-free survival (Stage IIIA)2,†

- In a prespecified exploratory subgroup analysis of patients with Stage IIIA disease, the Year 2 DFS rate was 92.7% for ALECENSA (95% CI: 86.4, 98.9) and 60.7% for chemotherapy (95% CI: 47.9, 73.5)2
93% of patients (stage IIIA) are DISEASE FREE AT Year 2 with ALECENSA2
Discover
ALECENSA IN
ALK+ RESECTED NSCLC
Explore
*These subgroup analyses are exploratory and not powered to demonstrate statistical significance between treatment arms and should therefore be interpreted with caution. †Stage IB (tumours ≥4 cm), II or IIIA NSCLC classified according to the 7th edition of the UICC/AJCC.2
AJCC: American Joint Committee on Cancer; ALK: anaplastic lymphoma kinase; CI: confidence interval; CNS: central nervous system; DFS: disease-free survival; HR: hazard ratio; NSCLC: non-small cell lung cancer; SmPC: Summary of Product Characteristics; UICC: Union for International Cancer Control.
1. Roche. ALECENSA (alectinib) Summary of Product Characteristics. 2024. Available here (accessed July 2024); 2. Wu Y-L, et al. N Engl J Med 2024;390(14):1265–1276.
- © 2024 F. Hoffmann-La Roche Ltd.
- M-XX-00017982; Date of preparation: July 2024
- Legal Statement
- Privacy Policy
- Cookies Preferences
Patients with ALK+ NSCLC are at high risk for brain metastases, which are associated with poor prognosis and have a substantial effect on health-related quality of life2
ALECENSA provides a 78% reduction in risk of CNS recurrence or death compared with platinum-based chemotherapy2,*
ALINA: CNS-DFS ITT (Stage IB–IIIA)2,3,†

Median survival follow-up was 27.8 months for ALECENSA and 28.4 months for chemotherapy2
ALINA: CNS-DFS ITT (Stage IB–IIIA)2,3,†
.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/alecensa-2/en/images/ALINAmobileversiongraphs_CNS-DFSITT(StageIB–IIIA).png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/alecensa-2/en/images/ALINAmobileversiongraphs_CNS-DFSITT(StageIB–IIIA).png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
Median survival follow-up was 27.8 months for ALECENSA and 28.4 months for chemotherapy2
CNS-DFS ITT2 |
ALECENSA |
Chemotherapy |
---|---|---|
Patient number, n |
130 | 127 |
Patients with event, n | 6 |
18 |
Death | 2 |
4 |
Brain recurrence | 4 | 14 |
CNS-DFS HR (95% CI) |
HR=0.22 (95% CI: 0.08, 0.58) |
|
|
No filter results
Discover
ALECENSA IN
ALK+ RESECTED NSCLC
*This analysis is exploratory and not powered to demonstrate statistical significance between treatment arms and should therefore be interpreted with caution. †Stage IB (tumours ≥4 cm), II or IIIA NSCLC classified according to the 7 edition of the UICC/AJCC.2
AJCC: American Joint Committee on Cancer; ALK: anaplastic lymphoma kinase; CI: confidence interval; CNS: central nervous system; DFS: disease-free survival; HR: hazard ratio; ITT: intention-to-treat; NSCLC: non-small cell lung cancer; SmPC: Summary of Product Characteristics; UICC: Union for International Cancer Control.
1. Roche. ALECENSA (alectinib) Summary of Product Characteristics. 2024. Available here (accessed July 2024); 2. Wu Y-L, et al. N Engl J Med 2024;390(14):1265–1276; 3. Solomon BJ, et al. Presented at the European Society for Medical Oncology Congress, 20–24 October 2023, Madrid, Spain.
- © 2024 F. Hoffmann-La Roche Ltd.
- M-XX-00017982; Date of preparation: July 2024
- Legal Statement
- Privacy Policy
- Cookies Preferences
*Stage IB (tumours ≥4 cm), II or IIIA NSCLC classified according to the 7th edition of the UICC/AJCC.2
AJCC: American Joint Committee on Cancer; ALK: anaplastic lymphoma kinase; CI: confidence interval; CNS: central nervous system; DFS: disease-free survival; HR: hazard ratio; ITT: intention-to-treat; NE: not estimable; NSCLC: non-small cell lung cancer; OS: overall survival; SmPC: Summary of Product Characteristics; UICC: Union for International Cancer Control.
1. Roche. ALECENSA (alectinib) Summary of Product Characteristics. 2024. Available here (accessed June 2024); 2. Wu Y-L, et al. N Engl J Med 2024;390(14):1265– 1276.